From: Clinical significance of the sub-classification of 71 cases mucinous breast carcinoma
Parameters | MBC (n=71) | p value | PMBC (n=48) | p value | ||
---|---|---|---|---|---|---|
MMBC (n=23) | PMBC (n=48) | PMBC-A (n=32) | PMBC-B (n=16) | |||
Age at operation | 14 (60.9%) | 24 (50.0%) | 0.390 | 14 (43.8%) | 10 (62.5%) | 0.220 |
≤64 | 9 (39.1%) | 24 (50.0%) | 18 (56.2%) | 6 (37.5%) | ||
>64 | ||||||
Pathological stage | 9 (39.1%) | 14 (29.2%) | 0.401 | 8 (25.0%) | 6 (37.5%) | 0.369 |
I | 14 (60.9%) | 34 (70.8%) | 24 (75.0%) | 10 (62.5%) | ||
II and III | ||||||
pTumor size | 11 (47.8%) | 14 (29.2%) | 0.123 | 8 (25.0%) | 6 (37.5%) | 0.175 |
≤2 cm | 12 (52.2%) | 34 (70.8%) | 24 (75.0%) | 10 (62.5%) | ||
>2 cm | ||||||
pLymph node status | 19 (82.6%) | 44 (91.7%) | 0.162 | 30 (93.8%) | 14 (87.5%) | 0.460 |
Negative | 4 (17.4%) | 4 (8.3%) | 2 (6.2%) | 2 (12.5%) | ||
Positive | ||||||
Lymphovascular invasion | 16 (69.6%) | 40 (83.3%) | 0.184 | 29 (90.6%) | 11 (68.8%) | 0.057 |
Negative | 7 (30.4%) | 8 (16.7%) | 3 (9.4%) | 5 (32.2%) | ||
Positive | ||||||
HR (ER and / or PR) | 1 (4.3%) | 2 (4.2%) | 0.454 | 1 (3.1%) | 1 (6.3%) | 0.453 |
Negative | 22 (95.7%) | 46 (95.8%) | 31 (96.9%) | 15 (93.7%) | ||
Positive | ||||||
HER2 status | 23 (100.0%) | 47 (97.9%) | 0.676 | 31 (96.9%) | 16 (100.0%) | 0.667 |
Negative | 0 (0.0%) | 1 (2.1%) | 1 (3.1%) | 0 (0.0%) | ||
Positive | ||||||
Ki67 | 17 (73.9%) | 46 (95.8%) | 0.010 | 30 (93.8%) | 16 (100.0%) | 0.439 |
Negative | 6 (26.1%) | 2 (4.2%) | 2 (6.2%) | 0 (0.0%) | ||
Positive | ||||||
Nuclear grade | 11 (47.8%) | 44 (91.7%) | < 0.001 | 30 (93.8%) | 14 (87.5%) | 0.306 |
1 | 12 (52.2%) | 4 (8.3%) | 2 (6.2%) | 2 (22.5%) | ||
2 and 3 | ||||||
EIC | 12 (52.2%) | 28 (58.3%) | 0.624 | 20 (62.5%) | 8 (50.0%) | 0.174 |
Negative | 11 (47.8%) | 20 (41.7%) | 12 (37.5%) | 8 (50.0%) | ||
Positive |